Safety profile for PEMAZYRE — 1 of 1

The safety profile of PEMAZYRE was investigated in the FIGHT–202 study in previously treated patients with CCA1

In FIGHT-202, the most common AR observed with PEMAZYRE was hyperphosphataemia1

Serious ARs

Selected ARs

Special Warnings and
Precautions for use

For further safety information, please refer to the PEMAZYRE Summary of Product Characteristics.1


Bar chart showing common ARs observed with PEMAZYRE

Patients (%)

Most common ARs (any grade)

Bar chart developed by Incyte, based on reference 1.